Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Next Previous
Search
Trial Profile

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nogapendekin alfa inbakicept (Primary) ; PD-L1-t-haNK (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Apr 2025 Planned initiation date changed to 3 Apr 2025 to 24 Apr 2025
    • 30 Mar 2025 Planned initiation date to 3 Apr 2025.
    • 27 Mar 2025 Planned initiation date changed from 26 Mar 2025 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top